JLE

Hépato-Gastro & Oncologie Digestive

MENU

New strategies for IBD patients Volume 16, issue 5, septembre-octobre 2009

Figures

See all figures

Author
Service gastroenterology, CHU St Etienne

Numerous abstracts have been presented at DDW 2009 on the topic of IBD. One-year data from the SONIC study show that Crohn’s patients refractory to steroids and who are naïve to immunomodulators respond to combination therapy with infliximab and azathioprine. Data from the STORI study show that more than half of Crohn’s disease patients who were in stable remission on combined therapy with immunosuppressors remained in clinical remission after infliximab discontinuation. These data will undoubtedly modify our therapeutic strategy. Several reassuring studies have shown that immunomodulators and biological therapy have no clear teratogenic effect. We also report failures or doubts on the efficacy of some new molecules. This is an incentive to optimize the available therapies.